Merck to buy VC-backed VelosBio for $2.75bn

Merck has agreed to acquire VelosBio Inc, a portfolio company of Pappas Capital, for $2.75 billion in cash.

5 November 2020•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.